10-Q: Motus GI Holdings Reports Q1 2024 Results, Cites Going Concern Uncertainty

Sentiment:

Quarterly Report 14 May 2024 4:23 PM

Motus GI Holdings reports a net loss of $2.1 million for Q1 2024 and expresses substantial doubt about its ability to continue as a going concern.

Capital raiseThe company is exploring a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System.The company may seek to sell common or preferred equity, convertible debt securities or seek other debt financing.The company may seek to raise cash through collaborative agreements or from government grants, as well as evaluate other strategic alternative transactions.

Worse than expectedThe company's net loss, limited revenue, and accumulated deficit are worse than expected.The going concern warning from the auditors indicates significant financial distress.

Summary

Motus GI Holdings, Inc. reported its financial results for the quarter ended March 31, 2024.
The company has developed the Pure-Vu System, a medical device cleared by the FDA to facilitate cleansing during colonoscopies and upper GI endoscopy procedures.
The company's revenue for the three months ended March 31, 2024, was $64,000, compared to $56,000 for the same period in 2023.
The net loss for the three months ended March 31, 2024, was $2.1 million, compared to a net loss of $4.4 million for the three months ended March 31, 2023.
Research and development expenses decreased to $0.5 million from $1.5 million year-over-year.
Sales and marketing expenses decreased to $0.2 million from $0.8 million year-over-year.
General and administrative expenses decreased to $1.5 million from $1.9 million year-over-year.
As of March 31, 2024, the company had cash and cash equivalents of $4.9 million and an accumulated deficit of $156.3 million.
The company is exploring strategic and financing alternatives to maximize stockholder value and accelerate commercialization.
There is substantial doubt about the company's ability to continue as a going concern if strategic transactions or additional financing are not available.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the going concern warning, continued losses, and limited revenue. While there are some positive trends in expense reduction, the overall financial situation is precarious.

Positives

Revenue increased slightly to $64,000 in Q1 2024 compared to $56,000 in Q1 2023.
Net loss decreased significantly from $4.4 million in Q1 2023 to $2.1 million in Q1 2024.
Operating expenses, including research and development, sales and marketing, and general and administrative, decreased compared to the same period last year.
The company received $2.7 million in gross proceeds from the exercise of Existing Warrants by the Holder, before deducting financial advisory fees and other offering expenses payable by the Company.

Negatives

The company has an accumulated deficit of $156.3 million as of March 31, 2024.
The company has generated limited revenues to date from the sale of products.
The company has never been profitable and has incurred significant net losses each year since its inception.
The company's auditors have raised substantial doubt about its ability to continue as a going concern.

Risks

The company's limited operating history and need for additional capital pose a significant risk.
The company's ability to execute its strategic restructuring program is uncertain.
The company's ability to enter into and consummate strategic alternatives is not guaranteed.
The company's dependence on the Pure-Vu System as its sole product is a risk factor.
The company's Pure-Vu System is not currently separately reimbursable through private or governmental third-party payors.
The company's ability to obtain regulatory approval or certification in different jurisdictions is uncertain.
The company's dependence on third parties to manufacture the Pure-Vu System is a risk.
The company's ability to maintain or protect the validity of its patents and other intellectual property is a risk.
The company's ability to retain key executives and medical and science personnel is a risk.
The company's ability to adequately support growth is a risk.
The company's ability to predict the financial impact of inflation on costs is a risk.
The company's ability to project the hospital medical device environment in the short term is a risk.
The impact of events occurring in the Middle East and the conflict taking place in Israel is a risk.

Future Outlook

The company expects to continue to incur net operating losses for the foreseeable future and is exploring strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System.

Management Comments

We are exploring a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System.
If a strategic transaction is not completed, or if additional financing is not available, we may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of our remaining assets.

Industry Context

The company operates in the medical device industry, specifically focusing on devices that improve visualization during gastrointestinal procedures. The market includes competitors offering similar solutions for bowel preparation and visualization during colonoscopies and upper GI procedures.

Comparison to Industry Standards

Given the limited revenue and going concern uncertainty, Motus GI's financial performance lags behind industry leaders in the medical device space.
Companies like Boston Scientific, Medtronic, and Olympus generate significantly higher revenues and have established market positions.
Motus GI's reliance on a single product and the lack of reimbursement codes pose challenges compared to diversified companies with multiple revenue streams and established reimbursement pathways.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer	Ravit Ram	TBD	2024-05-30	Resignation

Related Party Transactions

The Company recorded a license fee of $67 and $49, respectively, in relation to the Shared Space Agreement with Orchestra BioMed, Inc. for the three months ended March 31, 2024 and 2023.

Stakeholder Impact

Shareholders face significant risk due to the company's financial instability and potential for bankruptcy.
Employees face uncertainty due to potential restructuring and workforce reductions.
Customers may be affected by the company's ability to continue providing and supporting the Pure-Vu System.
Creditors face the risk of non-payment if the company is unable to secure additional financing or complete a strategic transaction.

Next Steps

The company will continue to explore strategic and financing alternatives.
The company will focus on commercializing the Pure-Vu System.
The company will seek additional capital to fund operations.

Key Dates

Date	Description
2016-09	Motus GI Holdings, Inc. was incorporated in Delaware, U.S.A.
2020-01	The Company entered into a license agreement with Orchestra BioMed, Inc.
2021-07-16	The Company entered into a loan facility with Kreos Capital VI (Expert Fund) LP.
2023-05-17	The Company entered into a securities purchase agreement with an accredited investor.
2023-10	The Company received 510(k) clearance from the FDA for the Pure-Vu EVS System for use in the upper GI tract and Gen 4 Colon.
2023-11-02	The Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15.
2023-12-18	The Company entered into a securities purchase agreement with certain purchasers pursuant to which it agreed to issue and sell, in a public offering.
2023-12-21	The closing of the Public Offering occurred.
2024-02-21	The Company and an investor entered into an agreement for the immediate exercise of certain outstanding warrants, the issuance of new warrants and the modification of other previously issued and outstanding warrants.
2024-02-26	The February 2024 Warrant Exercise closed.
2024-03-10	The Companys board of directors reserved a total of $900,000 for potential cash bonus payments to the Companys employees, contingent upon the achievement of a strategic transaction.
2024-03-31	End of the quarterly period.
2024-04-05	The Company received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the bid price of our common stock, par value $0.0001 per share, had closed at less than $1.00 per share over the previous 30 consecutive business days.
2024-04-25	Nasdaq issued a notification of removal from listing pursuant to the requirements of the Securities and Exchange Act of 1934.
2024-05-07	As of this date, 5,768,876 shares of the registrants common stock, $0.0001 par value, were issued and outstanding.
2024-05-12	Ravit Ram, our Chief Financial Officer, submitted a notice of resignation to the Company effective May 30, 2024.
2024-05-13	The board of directors approved the allocation of the total $900,000, in the event of a strategic transaction.
2024-05-13	Our common stock was listed for trading on the OTCQB under our current ticker symbol MOTS.
2024-05-14	Date of report.

Keywords

Pure-Vu System, Motus GI Holdings, Financial Results, Colonoscopy, Endoscopy, Going Concern, Warrant Exchange, OTCQB, Medical Device, FDA Clearance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.